{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:12:35Z","timestamp":1783548755206,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00404-015-3976-7","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T16:02:47Z","timestamp":1449763367000},"page":"509-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries"],"prefix":"10.1007","volume":"293","author":[{"given":"Mitra","family":"Niafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Pourafkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahan","family":"Porhomayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"key":"3976_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"SM Sirmans","year":"2013","unstructured":"Sirmans SM, Pate KA (2013) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1\u201313. doi: 10.2147\/CLEP.S37559","journal-title":"Clin Epidemiol"},{"issue":"6","key":"3976_CR2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89(6):2745\u20132749. doi: 10.1210\/jc.2003-032046","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3976_CR3","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/oxfordjournals.humrep.a136243","volume":"10","author":"AH Balen","year":"1995","unstructured":"Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS (1995) Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10(8):2107\u20132111","journal-title":"Hum Reprod"},{"issue":"2","key":"3976_CR4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejogrb.2005.03.010","volume":"122","author":"CJ Glueck","year":"2005","unstructured":"Glueck CJ, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy T, Sieve L (2005) Obesity and extreme obesity, manifest by ages 20\u201324\u00a0years, continuing through 32\u201341\u00a0years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 122(2):206\u2013212. doi: 10.1016\/j.ejogrb.2005.03.010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"2","key":"3976_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.OGX.0000109523.25076.E2","volume":"59","author":"RS Legro","year":"2004","unstructured":"Legro RS, Castracane VD, Kauffman RP (2004) Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 59(2):141\u2013154. doi: 10.1097\/01.OGX.0000109523.25076.E2","journal-title":"Obstet Gynecol Surv"},{"key":"3976_CR6","author":"M Niafar","year":"2015","unstructured":"Niafar M, Nader ND (2015) Adiponectin as serum biomarker of insulin resistance in patients with polycystic ovarian syndrome. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. doi: 10.3109\/09513590.2015.1008445","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"issue":"6","key":"3976_CR7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","volume":"33","author":"E Diamanti-Kandarakis","year":"2012","unstructured":"Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33(6):981\u20131030. doi: 10.1210\/er.2011-1034","journal-title":"Endocr Rev"},{"issue":"1","key":"3976_CR8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00404-013-2953-2","volume":"289","author":"AM Silva da","year":"2014","unstructured":"da Silva AM, de Andrade AC, Dias BH, da Silva Medeiros MA, Rao VS, das Chagas Medeiros F (2014) Elevated diastolic blood pressure in insulin-resistant polycystic ovarian syndrome patients. Arch Gynecol Obstet 289(1):119\u2013122. doi: 10.1007\/s00404-013-2953-2","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"3976_CR9","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/0016-5085(94)90831-1","volume":"107","author":"JJ Holst","year":"1994","unstructured":"Holst JJ (1994) Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107(6):1848\u20131855","journal-title":"Gastroenterology"},{"issue":"8571","key":"3976_CR10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7\u201336: a physiological incretin in man. Lancet 2(8571):1300\u20131304","journal-title":"Lancet"},{"issue":"8","key":"3976_CR11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/dc07-0310","volume":"30","author":"A Mari","year":"2007","unstructured":"Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O (2007) Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 30(8):2032\u20132033. doi: 10.2337\/dc07-0310","journal-title":"Diabetes Care"},{"issue":"9662","key":"3976_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, Group L-S","year":"2009","unstructured":"Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, Group L-S (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662):473\u2013481. doi: 10.1016\/S0140-6736(08)61246-5","journal-title":"Lancet"},{"issue":"3","key":"3976_CR13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157488412800958686","volume":"7","author":"G Derosa","year":"2012","unstructured":"Derosa G, Maffioli P (2012) GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 7(3):214\u2013228","journal-title":"Curr Clin Pharmacol"},{"key":"3976_CR14","first-page":"672658","volume":"2012","author":"M Monami","year":"2012","unstructured":"Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E (2012) Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012:672658. doi: 10.1155\/2012\/672658","journal-title":"Exp Diabetes Res"},{"issue":"1","key":"3976_CR15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dom.12175","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (2014) Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16(1):38\u201347. doi: 10.1111\/dom.12175","journal-title":"Diabetes Obes Metab"},{"key":"3976_CR16","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344:d7771. doi: 10.1136\/bmj.d7771","journal-title":"BMJ"},{"issue":"11","key":"3976_CR17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s12325-014-0164-2","volume":"31","author":"Q Du","year":"2014","unstructured":"Du Q, Wang YJ, Yang S, Zhao YY, Han P (2014) Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther 31(11):1182\u20131195. doi: 10.1007\/s12325-014-0164-2","journal-title":"Adv Ther"},{"key":"3976_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12902-015-0005-6","volume":"15","author":"H Kahal","year":"2015","unstructured":"Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL (2015) The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord 15:14. doi: 10.1186\/s12902-015-0005-6","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"3976_CR19","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R (2008) Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93(7):2670\u20132678. doi: 10.1210\/jc.2008-0115","journal-title":"J Clin Endocrinol Metab"},{"key":"3976_CR20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fendo.2014.00140","volume":"5","author":"CB Rasmussen","year":"2014","unstructured":"Rasmussen CB, Lindenberg S (2014) The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne) 5:140. doi: 10.3389\/fendo.2014.00140","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"3976_CR21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07435800.2014.966385","volume":"40","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A (2015) Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res 40(3):133\u2013138. doi: 10.3109\/07435800.2014.966385","journal-title":"Endocr Res"},{"issue":"1","key":"3976_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A (2015) A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens) 14(1):81\u201390","journal-title":"Hormones (Athens)"},{"issue":"3","key":"3976_CR23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A (2014) Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 170(3):451\u2013459. doi: 10.1530\/EJE-13-0797","journal-title":"Eur J Endocrinol"},{"key":"3976_CR24","author":"M Jensterle","year":"2014","unstructured":"Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A (2014) Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. doi: 10.3109\/07435800.2014.966385","journal-title":"Endocr Res"},{"issue":"1","key":"3976_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12902-015-0005-6","volume":"15","author":"H Kahal","year":"2015","unstructured":"Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL (2015) The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocrine Disord 15(1):14. doi: 10.1186\/s12902-015-0005-6","journal-title":"BMC Endocrine Disord"},{"issue":"9701","key":"3976_CR26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Hakim A, Madsen J, Rasmussen MF, Lean ME, Group NNS (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701):1606\u20131616. doi: 10.1016\/S0140-6736(09)61375-1","journal-title":"Lancet"},{"issue":"6","key":"3976_CR27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","volume":"33","author":"J Rosenstock","year":"2010","unstructured":"Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M (2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33(6):1173\u20131175. doi: 10.2337\/dc09-1203","journal-title":"Diabetes Care"},{"issue":"6","key":"3976_CR28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/humrep\/13.6.1502","volume":"13","author":"AM Clark","year":"1998","unstructured":"Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ (1998) Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13(6):1502\u20131505","journal-title":"Hum Reprod"},{"issue":"4","key":"3976_CR29","first-page":"1470","volume":"84","author":"MM Huber-Buchholz","year":"1999","unstructured":"Huber-Buchholz MM, Carey DG, Norman RJ (1999) Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 84(4):1470\u20131474. doi: 10.1210\/jcem.84.4.5596","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3976_CR30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cen.12369","volume":"81","author":"H Kahal","year":"2014","unstructured":"Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL (2014) Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol 81(4):523\u2013528. doi: 10.1111\/cen.12369","journal-title":"Clin Endocrinol"},{"issue":"1","key":"3976_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1385\/ENDO:30:1:13","volume":"30","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E (2006) Insulin resistance in PCOS. Endocrine 30(1):13\u201317. doi: 10.1385\/ENDO:30:1:13","journal-title":"Endocrine"},{"issue":"6","key":"3976_CR32","first-page":"774","volume":"18","author":"A Dunaif","year":"1997","unstructured":"Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18(6):774\u2013800. doi: 10.1210\/edrv.18.6.0318","journal-title":"Endocr Rev"},{"issue":"7","key":"3976_CR33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.ijo.0801994","volume":"26","author":"A Gambineri","year":"2002","unstructured":"Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R (2002) Obesity and the polycystic ovary syndrome. Int J Obesity Relat Metab Disord J Int Assoc Study Obesity 26(7):883\u2013896. doi: 10.1038\/sj.ijo.0801994","journal-title":"Int J Obesity Relat Metab Disord J Int Assoc Study Obesity"},{"issue":"5","key":"3976_CR34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2337\/diab.45.5.615","volume":"45","author":"J Rincon","year":"1996","unstructured":"Rincon J, Holmang A, Wahlstrom EO, Lonnroth P, Bjorntorp P, Zierath JR, Wallberg-Henriksson H (1996) Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes 45(5):615\u2013621","journal-title":"Diabetes"},{"issue":"3","key":"3976_CR35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1152\/physrev.1995.75.3.473","volume":"75","author":"GM Reaven","year":"1995","unstructured":"Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75(3):473\u2013486","journal-title":"Physiol Rev"},{"issue":"5","key":"3976_CR36","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1210\/jc.2004-2190","volume":"90","author":"N Pitteloud","year":"2005","unstructured":"Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ (2005) Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90(5):2636\u20132641. doi: 10.1210\/jc.2004-2190","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"3976_CR37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/humrep\/12.suppl_1.53","volume":"12","author":"JE Nestler","year":"1997","unstructured":"Nestler JE (1997) Insulin regulation of human ovarian androgens. Hum Reprod 12(Suppl 1):53\u201362","journal-title":"Hum Reprod"},{"issue":"2","key":"3976_CR38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0026-0495(90)90070-S","volume":"39","author":"L Poretsky","year":"1990","unstructured":"Poretsky L, Bhargava G, Saketos M, Dunaif A (1990) Regulation of human ovarian insulin receptors in vivo. Metab Clin Exp 39(2):161\u2013166","journal-title":"Metab Clin Exp"},{"issue":"2","key":"3976_CR39","first-page":"654","volume":"80","author":"R Pasquali","year":"1995","unstructured":"Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, Flamia R, Biscotti M, Vicennati V (1995) Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 80(2):654\u2013658. doi: 10.1210\/jcem.80.2.7852532","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3976_CR40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2337\/dc12-0940","volume":"36","author":"M Yang","year":"2013","unstructured":"Yang M, Liu R, Li S, Luo Y, Zhang Y, Zhang L, Liu D, Wang Y, Xiong Z, Boden G, Chen S, Li L, Yang G (2013) Zinc-alpha2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. Diabetes Care 36(5):1074\u20131082. doi: 10.2337\/dc12-0940","journal-title":"Diabetes Care"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-015-3976-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-015-3976-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-015-3976-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T05:59:47Z","timestamp":1567403987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-015-3976-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3976"],"URL":"https:\/\/doi.org\/10.1007\/s00404-015-3976-7","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]}}}